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A stereoselective strategy for the rapid acquisition of the
complete framework (dideoxyottelione A) of the promising
cytotoxic agent ottelione A, with four contiguous stereogenic
centres on a hydrindane skeleton and a sensitive 4-methyl-
enecyclohex-2-enone functionality, from the readily availa-
ble Diels–Alder adduct of 1,2,3,4-tetrachloro-
5,5-dimethoxycyclopentadiene and norbornadiene, is
delineated.
Towards the end of 1998, the isolation and structure determina-
tion of two novel, diastereomeric 4-methylenecyclohex-
2-enone moiety-bearing natural products, otteliones A and B,
from the fresh water plant Ottelia alismoides that grows
partially under water, was reported.1 While ottelione B was
assigned structure 1, even the most incisive analyses of the
NMR data and modelling did not permit unambiguous assign-
ment to ottelione A. For ottelione A, structures 2a and 2b were
considered and on the basis of available data 2a was very much
favoured without fully ruling out 2b.1 Ottelione A was also
found to be identical with the compound reported earlier in the
patent literature by Leboul and Provost at Rhone-Poulenc
Rorer.2 Our interest in otteliones A and B was aroused by the
observation of remarkable antitumor and antileukemia activity
exhibited by them.123 It was shown that 1 and 2 inhibit tubulin
polymerisation into microtubules in a manner reminiscent of
colchicine, vincristine and vinblastine. When subjected to in
vitro screening against a panel of ca. 60 human tumor cell lines
at NCI, both 1 and 2 showed remarkable cytotoxicity against
most of the cell lines at nM–pM concentrations.1 Such a
promising biological activity profile, the unusual bicyclic
structure with four stereogenic centres, the presence of a
sensitive 4-methylenecyclohex-2-enone moiety4 and the un-
certainty associated with the structure assigned to ottelione A 2
prompted us to explore synthetic approaches towards this novel
molecule. Herein, we describe a stereoselective and flexible
approach, targeted towards the favoured formulation 2a for
Scheme 1 Reagents and conditions: i, reflux, 14 h, 93%; ii, OsO4, NMO, 24
h, 90%, then Na/NH3, THF, EtOH, 15 min, 65%; iii, NaIO4, aq. THF, 30
min, 85%; iv, MePPh3Br, ButOK, THF, 10 min, then NaBH4, MeOH, 15
min, 42% for two steps; v, TsCl, Py, 4 h, 95%; vi, PhMgBr, CuBr, 30 min,
62%, then Amberlyst-15, acetone, 2 h, 95%; vii, 30% H2O2–NaOH, MeOH,
12 h, then LiAlH4, THF, 2 h, 50–60% for two steps; viii, PDC, EtOAc, cat.
AcOH, 2 h, 75%; ix, MsCl, DMAP, CH2Cl2, 4 h, then DBU, CH2Cl2, 45
min, 90% for two steps.
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ottelione A, which has resulted in the acquisition of the
complete framework of ottelione A and set the stage for the
synthesis of the natural product.
The key element of our projected synthesis of ottelione A 2a
was the identification of the stereochemically well-defined
tricyclic compound 3, 5 readily available through inverse
electron demand Diels–Alder reaction between 1,2,3,4-tetra-
chloro-5,5-dimethoxycyclopentadiene and norbornadiene, as a
propitious starting point (Scheme 1). In 3, the bicyclic
hydrindane framework as well as all the four stereogenic centres
present in ottelione A are firmly imbedded (see bold lines in 3)
and the main task was to disengage the requisite framework
from 3, preserving the stereochemical features, and sequentially
generate the complex and extensive functionalization pattern
present in the target molecule 2a.
Regioselective OsO4-mediated dihydroxylation of the un-
substituted norbornene double bond in 35 and reductive
dehalogenation furnished the cis-diol 4.6 Periodate cleavage led
to the dialdehyde 5 which was directly subjected to controlled
mono-Wittig olefination and the remaining aldehyde function-
ality was reduced to furnish 6. Tosylation of the hydroxy group
in 6 to 7 and CuI mediated cross-coupling reaction with
PhMgBr and acetal deprotection readily led to 86 with the
correct stereochemical disposition at all the four stereogenic
centres (cf. 1, 3, 3a and 7a positions in 2a)1 and the desired two
substituents on the five-membered ring. The hydrindane
framework from the key compound 8 was extracted through
Baeyer–Villiger oxidation to two regioisomeric lactones
(55:45) and LAH reduction to furnish the diols 9 and 10,
respectively. PDC oxidation of 9 and 10 led to the enones 116
and 13,6 respectively, and extensive high field 2D NMR studies
on these enones established their structural identity.6 The
sensitive 4-methylenecyclohex-2-enone moiety from 11 was
generated quite uneventfully through conversion of the primary
hydroxy group to the mesylate and DBU mediated elimination
to yield dideoxyottelione A 126 (Scheme 1). The 1H and 13C
NMR data for 12 exhibited remarkable similarity to that of the
natural product 2a, as the only difference between them is the
presence of the aromatic substitution in the latter. In a similar
manner, enone 13 was transformed to 14,6 a regioisomer of the
natural series in which the benzyl and vinyl moieties are
interchanged.
In short, we have outlined a simple and flexible strategy,
emanating from abundantly available starting materials, to-
wards a promising cytotoxic natural product ottelione A 2a. Our
approach can be readily adapted to the synthesis of 2a itself
through minor tactical modifications and is inherently well-
suited to delivering a variety of analogues for biological
evaluation. Efforts along these lines are underway and will be
reported shortly.
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